• Novartis has been granted an option to in-license global rights of MP0420 and MP0423 - multi-targeted direct-acting antiviral therapeutic candidates demonstrating potential efficacy against…
· Swiss Government will pay a reservation fee for the right to purchase up to 3.2 million doses of anti-COVID-19 DARPin® candidate, MP0420, for both…
Symphogen becomes the antibody center of excellence within Servier strengthening the Group’s pipeline
Paris (France), June 4, 2020 – Servier, an independent…
- DARPin® antiviral candidates demonstrate low picomolar potency in live virus assay
- Candidate construction complete; two candidates ready for preclinical development & manufacturing
· First trispecific anti-COVID-19 therapeutic program: targets three parts of the viral “spike” protein with one drug candidate for broad inhibition of infection and mitigation…
- Servier strengthens its R&D pipeline by acquiring Symphogen’s antibody pipeline and next-generation antibody technologies.
- Symphogen becomes the antibody center of excellence within…
• Sandip Kapadia, Michael Vasconcelles and Vito J. Palombella nominated for election to the Board of Directors of Molecular Partners at the upcoming Annual General…
Zurich-Schlieren, SWITZERLAND—Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company that is developing a new class of drugs known as DARPin® therapies*, today announced that…
Filing includes data from two Phase 3 trials which evaluated the safety and efficacy of Abicipar quarterly dosing regimen
All content © 2024
Legal Disclaimer | Privacy Notice
Powered by 